...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
【24h】

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)

机译：使用生长抑素类似物治疗胃肠道胰腺神经内分泌肿瘤的患者和护士经验：生长抑素治疗经验试验（STREET）的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Evaluate patients’ and nurses’ experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogelsup?/sup (Somatulinesup?/sup autogelsup?/sup, deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatinsup?/sup LARsup?/sup, intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants’ most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments. Nurses were identified via patients completing their questionnaires. Resource use was sourced from Swedish prescription registry records. The planned sample size was 200, based on an estimated proportion of 0.50 and ±7% precision. Results: 119/156 patients (n=53, lanreotide; n=66, octreotide) and 43/53 nurses (n=22, lanreotide; n=21, octreotide) completed questionnaires. Despite smaller recruitment than planned, the endpoint precision was ±9% with 119 participants, and still considered reasonable. More octreotide-treated patients reported problems (18% vs none; P =0.001) and experienced moderate-to-high anxiety pre-injection (11% vs 2%). Patients had similar physical HRQoL scores overall (Short Form-12 mean composite scores: physical: 39.4 vs 37.6; mental: 50.7 vs 49.6). The mean number of lanreotide and octreotide doses dispensed per year were 11.1 and 12.6, respectively ( P 0.05). In the lanreotide group, 28% self-injected, while 29% were not aware they could self-inject. In the octreotide group, 3% self-injected and 73% were unaware of the availability of an SSA for self-injection. Most patients (61%) felt well-informed about their disease and treatment. Nurses were generally experienced and felt confident and well-informed about giving SSA injections; however, only 12% felt well-informed about the disease and treatment. Conclusion: Those treated with lanreotide reported fewer injection problems and experienced less pre-injection anxiety than those treated with octreotide. SSA choice did not appear to affect patients’ HRQoL. Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection.
机译：目的：使用生长抑素类似物兰瑞肽autogel ？（Somatuline ？ autogel ？评估患者和护士的经历，包括注射问题的频率。 >，深层皮下注射）和奥曲肽长效释放（LAR）（Sandostatin ？ LAR ？，肌肉内）治疗胃肠道胰腺神经内分泌肿瘤（GEP-NETs）。方法：对瑞典2个NET中心进行的观察性横断面研究。根据参与者最近的注射经验，向被奥曲肽或兰瑞肽治疗的GEP-NET患者以及接受这些治疗的护士发送问卷。通过填写调查表的患者来确定护士。资源使用来自瑞典处方注册记录。计划的样本量为200，基于估计比例0.50和±7％的精度。结果：119/156位患者（n = 53，兰曲肽; n = 66，奥曲肽）和43/53护士（n = 22，lanreotide; n = 21，奥曲肽）完成了问卷。尽管招募人数少于计划的人数，但有119名参与者的终点精确度为±9％，仍然被认为是合理的。接受奥曲肽治疗的患者报告有问题（18％vs.无; P = 0.001），并且注射前经历了中度到高度焦虑（11％vs. 2％）。患者的整体HRQoL得分总体上相似（12年级平均综合得分短：身体：39.4 vs 37.6;精神：50.7 vs 49.6）。每年平均分配的兰瑞肽和奥曲肽剂量分别为11.1和12.6（P <0.05）。在兰瑞肽组中，有28％的人自行注射，而29％的人不知道自己可以自行注射。在奥曲肽组中，3％的自我注射和73％的人不知道SSA可用于自我注射。大多数患者（61％）对自己的疾病和治疗情况了解透彻。护士通常经验丰富，对注射SSA充满信心并了解情况。但是，只有12％的人对疾病和治疗情况有充分的了解。结论：与奥曲肽治疗组相比，兰瑞肽治疗组报告的注射问题更少，注射前的焦虑程度更低。 SSA的选择似乎并未影响患者的HRQoL。一些接受奥曲肽治疗的患者没有意识到具有自我注射灵活性的SSA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号